ORIC Pharmaceuticals Receives $53 Million to Develop Prostate Cancer Drug Candidate

ORIC Pharmaceuticals Receives $53 Million to Develop Prostate Cancer Drug Candidate
ORIC Pharmaceuticals issued a press release announcing a B Series financing of $53 million to support the development of the company’s initial drug candidate’s first clinical trial and to further develop additional therapies in the company’s pipeline. ORIC’s first drug candidate will focus on the glucocorticoid receptor (GR) as a target for androgen receptor (AR) resistance in prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *